QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS
Retrieved on:
Monday, November 29, 2021
Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Infectious Diseases, Genetics, Other Health, Patient, Genetically modified bacteria, Latent tuberculosis, Automation, World Health Organization, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DiaSorin, Adoption, Protein, CEO, Sale, Death, Company, Hospital, NYSE, FTSE MIB, WHO, Partnership, World, Group, Tuberculin, Knowledge, Â, Workflow, SEC, Budget, Blood, IVD, Solution, PMA, U.S. Securities and Exchange Commission, DNA, Research, FTSE, List of life sciences, Marketing, RNA, LTBI, Molecular diagnostics, FDA, Life, DIA, XL, TB, QGEN, XS, Growth, Infection, Disease, IGRA, Food, Gold, Pharmaceutical industry, Medical device, Vaccine, Fine chemical, QIAGEN, DiaSorin, QIAGEN, DIASORIN
The addition of the LIAISON XS platform will open up new joint opportunities for us to reach new customer segments requiring lower-throughput options.
Key Points:
- The addition of the LIAISON XS platform will open up new joint opportunities for us to reach new customer segments requiring lower-throughput options.
- Carlo Rosa, CEO of DiaSorin Group, commented: Today we announce the approval of our first PMA assay available on the LIAISON XS platform.
- This solution is a key milestone of our LIAISON XS strategy in the U.S., where the test was already successfully launched in 2019 on our LIAISON XL platform.
- LIAISON QuantiFERON-TB Gold Plus is an interferon-gamma release assay (IGRA) developed by QIAGEN and DiaSorin to offer streamlined laboratory automation for latent TB screening.